Ro 13-9904/001, a Novel Potent and Long-acting Parenteral Cephalosporin

Overview

Journal J Antibiot (Tokyo)

Specialties Infectious Diseases
Pharmacology

Date 1980 Jul 1

PMID 6967869

Citations 23

Authors

R Reiner

U Weiss

U Brombacher

P Lanz

M Montavon

A FURLENMEIER

P Angehrn

P J Probst

Affiliations

Soon will be listed here.

Abstract

Ro 13-9904/001 is a novel parenteral cephalosporin antibiotic with potent in vitro activity against a wide range of beta-lactamase-producing and non-producing pathogens. In addition, Ro 13-9904/001 proved to possess a very long plasma half-life and, as a consequence, high prophylactic in vivo effectiveness.

Citing Articles

Endotoxin-Induced Sepsis on Ceftriaxone-Treated Rats' Ventilatory Mechanics and Pharmacokinetics.

Simoes J, Rodrigues R, Zavan B, Emidio R, Soncini R, Boralli V Antibiotics (Basel). 2024; 13(1).

PMID: 38247642 PMC: 10812549. DOI: 10.3390/antibiotics13010083.

The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.

Turner J, Muraoka A, Bedenbaugh M, Childress B, Pernot L, Wiencek M Front Microbiol. 2022; 13:807955.

PMID: 35401470 PMC: 8988990. DOI: 10.3389/fmicb.2022.807955.

Molecular Features of Cephalosporins Important for Activity against Antimicrobial-Resistant .

Turner J, Connolly K, Aberman K, Fonseca 2nd J, Singh A, Jerse A ACS Infect Dis. 2021; 7(2):293-308.

PMID: 33533239 PMC: 9847585. DOI: 10.1021/acsinfecdis.0c00400.

Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.

Duncan C, Barr D, Seaton R Int J Clin Pharm. 2012; 34(3):410-7.

PMID: 22527482 DOI: 10.1007/s11096-012-9637-z.

Comparison of the activity of ionophores with other antibacterial agents against anaerobes.

Watanabe K, Watanabe J, Kuramitsu S, Maruyama H Antimicrob Agents Chemother. 1981; 19(4):519-25.

PMID: 7247375 PMC: 181469. DOI: 10.1128/AAC.19.4.519.